RBC Capital Starts Johnson & Johnson (JNJ) at Outperform, "attractively valued and poised to deliver MSD revenue growth"

RBC Capital analyst Shagun Singh initiates coverage on Johnson & Johnson (NYSE: JNJ) with a Outperform rating and a price target of $178.00.

The analyst comments: "JNJ is a global healthcare company uniquely positioned with Pharma and MedTech under one umbrella. JNJ has unlocked potential with the consumer separation and is poised to drive: (1) Pharma franchise to deliver competitive growth, including in 2H of decade aided by its pipeline (five +$5B and 12 +$1B revenue potential, +65 filings 2026-30); and (2) MedTech franchise to be a top-grower with portfolio shifting and focused innovation. JNJ is attractively valued and poised to deliver MSD revenue growth with 1.5-2.0x leverage to EPS while returning 60% FCF to shareholders while keenly focusing on M&A."

For an analyst ratings summary and ratings history on Johnson & Johnson click here. For more ratings news on Johnson & Johnson click here.

Shares of Johnson & Johnson closed at $155.52 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy